Sanofi touts Phase 3 Sar­clisa da­ta in mul­ti­ple myelo­ma as it plays catch-up with J&J’s Darza­lex

Sanofi re­port­ed pos­i­tive Sar­clisa da­ta from a reg­is­tra­tional test in cer­tain new­ly-di­ag­nosed mul­ti­ple myelo­ma pa­tients, with the com­pa­ny an­tic­i­pat­ing a US launch as ear­ly as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER